Rapid Assessment of Sentinel Lymph Node Metastasis Status Using a Pan-CK-targeting NIR-II Fluorescent Probe in Breast Cancer
Recruiting
Observational Study
Breast Cancer Metastatic
Sentinel Lymph Node
Sentinel Lymph Node Biopsy (SLNB)
Metastasis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 75
- Sex
- Female
- Study type
- Observational
- Participants needed
- 60 (estimated)
- Sponsor
- Yunnan Cancer Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Breast malignant tumors are a serious threat to women's health, and the current treatment for breast malignant tumors is still dominated by surgery, but the problems faced by patients after surgery such as edema and tumor recurrence are still relatively common, and the high recurrence rate and the occurrence of postoperative complications are closely related to the removal of metastatic lymph node…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adult patients between 18-75 years of age
* Patients presenting with a breast nodule or mass presumed to be resectable on pre-operative assessment
* Breast cancer patients who are scheduled to undergo sentinel lymph node biopsy or axillary lymph node dissection;
* Good operati…
Contacts